Corteva Subsidiary Reaches Key Threshold in Exchange Offers

By Tamara Parker • Thursday, August 20 10:55 • Permanent Link

Corteva said Vylor, its wholly owned subsidiary, had received enough early tenders and consents to clear the key threshold for its exchange offers tied to EIDP’s notes.

By the Aug. 19 early tender deadline, holders had tendered:

$431.634 million of EIDP’s 2.300% senior notes due 2030, or 86.33% of the $500 million outstanding
$468.434 million of EIDP’s 5.125% senior notes due 2032, or 93.69% of the $500 million outstanding
$524.868 million of EIDP’s 4.800% senior notes due 2033, or 87.48% of the $600 million outstanding

Across the three series, that adds up to $1.425 billion tendered out of $1.6 billion outstanding.

Corteva said it had received the requisite consents to adopt the base indenture amendments for all EIDP notes, along with majority consents for the supplemental indenture amendments for each series.

The company also pushed the expiration date for each exchange offer and consent solicitation from Sept. 3 to Sept. 29, 2026.

For holders who tendered by the early deadline and are accepted, the cash component is set at about:

$2.90 per $1,000 principal amount for the 2030 notes
$2.67 per $1,000 principal amount for the 2032 notes
$2.86 per $1,000 principal amount for the 2033 notes

Those early-tender holders will also receive an equal principal amount of new Vylor notes. Holders who tender after the early deadline but by the new expiration date will receive $970 principal amount of Vylor notes per $1,000 principal amount of EIDP notes, with no cash consideration.

Corteva said the separation of its crop protection business and seed business is still expected around Oct. 1, 2026, and the exchange offers are conditioned on that deal closing. The market has reacted to these announcements by moving the company's shares 2.6% to a price of $80.61. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.